News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
The company will be submitting the responses to US FDA observations within stipulated timeline
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
The inspection concluded with no observations
Time to combine innovation, access and technology to deliver positive patient outcomes
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Subscribe To Our Newsletter & Stay Updated
